Atrial fibrillation

[키워드] 1:1 Ability Ability to walk Activation adhere administer ambulatory patient anatomical Anticoagulant treatment anticoagulation antiplatelet Atrial fibrillation baseline bleeding Blinding block size body temperature calculated Cardiovascular events characterized Chemotherapy clearance clinical benefit clinically Coagulation Coagulopathy Comorbidity Comparator group conducted contraindication control group coronary syndrome coronavirus cough COVID-19 creatinine criteria Critical current death defined diagnosed diagnosed with COVID-19 Diagnosis Disseminated intravascular coagulation dissemination dose Efficacy elderly element eligibility criteria eligible enoxaparin enrolment event event rate experimental group Face mask FIVE fixed heart failure help heparin-induced thrombocytopenia Hospitalization hospitals hygiene hypersensitivity impairment IMPROVE In-hospital Inflammation information injection inoperable Intervention intervention group invasive Ischemia Laboratory lack Last Liver disease lower limb major bleeding malignancy multicentre Myocardial number objective Older Open-label outcome parameter participant Participation Patient performed Platelet Positive test Presence prevention protocol provided Radiotherapy randomised randomised controlled trial randomization randomization ratio Randomized Randomized controlled trial receive reduce renal respiratory symptom resulting risk factor Sample size SARS-CoV2 secondary Seven Shortness of breath sore throat Spinal cord injury status Stratified randomization stroke Study protocol Support surgical survival symptomatic the patient therapy Thromboprophylaxis thrombosis total sample size Transport trauma Travel treated Treatment undergo university university hospital Venous Thromboembolism vessel viral disease VTE website
[DOI] 10.1186/s13063-020-04678-4 PMC 바로가기 [Article Type] Letter